Hanyu Pharmaceutical Listing Gem

Yuan Jiancheng introduced that "one center" is the R & D center of polypeptide drugs, and the "two markets" is the domestic and international market. "One target" is positioned to achieve over 10 billion yuan in sales revenue in the next ten years. "A new class of drugs" refers to the development of a new class of peptide drugs.

Speaking of the realization of the company's strategic objectives, the executives of Han Yu pharmaceutical company are full of confidence.

Ceng Shaogui, chairman of the company, said: "10 years ago, we thought that the listing of Han Yu pharmaceutical was only a dream, but now it is confident that the company will achieve a goal of selling tens of billions of dollars in the next 10 years."

Yuan Jiancheng believes that the international drug market is huge and has the potential to expand to the emerging market countries. The sales of polypeptide drugs increase by more than 20% over the past year. After more than ten years of experience in the industry, the level of research and development and the expansion of the talent advantage, Han has the ability to better grasp the development opportunities of the polypeptide medicine industry in China and the world, and to make the national brand of Han Yu pharmaceutical bigger and stronger.

Yuan Jiancheng also said that from 2011 to 2013, the company's revenue and other financial indicators will continue to maintain a relatively high inertia growth rate.

"According to the expectation, in 2013, the products that Han Yu had invested in R & D overseas will be listed. With the completion of the high-end injection production base in the investment and investment project of the National Bio pharmaceutical industrialization base in Longgang District of Shenzhen, and the increase in the number of new products listed in China, Han Yu pharmaceutical industry will usher in the rapid growth of the company's business in 2013."